肿瘤医院团队正探索卵巢癌治疗“中国方案” - 2021年02月05日

Research led by local medical experts found clinical evidence for a new therapy to treat women with ovarian cancer, the world’s first such research related to the effects of the Poly ADP-ribose polymerase (PARP) inhibitor on Chinese ovarian cancer patients, according to officials from Shanghai Cancer Center.
The research was published in the Annals of Oncology journal.
The PARP inhibitor is considered a promising development for ovarian cancer treatment.